Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Ironwood Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company discovers, develops, manufactures, and commercializes marketed drugs. Ironwood products used in treatments of cholesterol, gastrointestinal, and cardiovascular diseases, as well as pain, inflammation, and others.
Website: ironwoodpharma.com



Growth: Bad revenue growth rate -27.9%, there is slowdown compared to average historical growth rates 1.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -227.3%. On average the margin is decreasing unsteadily. Gross margin is high, +99.3%. In the last quarter the company beat the estimated EPS, +4.2%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -108.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is -1.5% higher than minimum and 62.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -9.9x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $1.5 mln (-0.147% of cap.)

Key Financials (Download financials)

Ticker: IRWD
Share price, USD:  (-1.5%)5.745
year average price 9.93  


year start price 10.98 2023-06-19

max close price 15.45 2024-02-14

min close price 5.83 2024-06-14

current price 5.75 2024-06-17
Common stocks: 153 837 992

Dividend Yield:  0.0%
Last revenue growth (y/y):  -27.884615384615
Last growth of EBITDA (y/y):  -80.327868852459
Historical revenue growth:  1.740143515977
Historical growth of EBITDA:  -10.494969176441
EV / Sales: 3.5x
Margin (EBITDA LTM / Revenue): -227.3%
Fundamental value created in LTM:
Market Cap ($m): 884
Net Debt ($m): 569
EV (Enterprise Value): 1 453
Price to Book: -2.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-06-07accesswire.com

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Contact Them

2024-06-04accesswire.com

The Schall Law Firm Declares an Inquiry into Accusations Against Ironwood Pharmaceuticals, Inc. and Advocates for Investors with Losses to Reach Out

2024-06-03accesswire.com

IRWD INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

2024-06-02accesswire.com

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

2024-05-31accesswire.com

ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

2024-05-10Zacks Investment Research

Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates

2024-04-30InvestorPlace

Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks

2024-03-05InvestorPlace

It's Time! 3 Failing Biotech Stocks to Sell Right Now

2024-02-29InvestorPlace

Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?

2024-02-16Zacks Investment Research

Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IRWD IRWD IRWD IRWD IRWD IRWD IRWD
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-09 2024-02-16 2023-11-09 2023-08-09 2023-05-04 2023-02-16 2022-11-03
acceptedDate 2024-05-09 16:46:11 2024-02-16 07:01:34 2023-11-09 16:18:17 2023-08-09 16:02:57 2023-05-04 16:05:54 2023-02-16 17:21:07 2022-11-03 16:06:19
calendarYear 2024 2023 2023 2023 2023 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 75M 118M 114M 107M 104M 107M 109M
costOfRevenue 513 000 512 000 507 000 0 0 0 0
grossProfit 74M 117M 113M 107M 104M 107M 109M
grossProfitRatio 0.993 0.996 0.996 1 1 1 1
researchAndDevelopmentExpenses 25M 35M 33M 1 125M 13M 10M 12M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 38M 38M 36M 52M 31M 28M 29M
otherExpenses 0 6M 0 0 0 0 0
operatingExpenses 63M 73M 69M 1 178M 44M 39M 40M
costAndExpenses 63M 73M 69M 1 178M 44M 39M 40M
interestIncome 1M 1M 2M 9M 7M 5M 3M
interestExpense 7M 8M 10M 2M 2M 2M 1M
depreciationAndAmortization 513 000 512 000 507 000 22M 7M 5M 3M
ebitda 12M 45M 46M -1 061M 67M 74M 71M
ebitdaratio 0.16 0.382 0.408 -9.884 0.647 0.689 0.656
operatingIncome 11M 44M 40M -1 083M 60M 68M 68M
operatingIncomeRatio 0.153 0.378 0.352 -10.087 0.578 0.638 0.63
totalOtherIncomeExpensesNet -6M -14M -5M -13M 6M 4M 1M
incomeBeforeTax 5M 30M 32M -1 076M 66M 72M 70M
incomeBeforeTaxRatio 0.066 0.258 0.281 -10.022 0.633 0.674 0.643
incomeTaxExpense 9M 32M 18M 13M 20M 23M 20M
netIncome -4M -1M 15M -1 062M 46M 49M 50M
netIncomeRatio -0.056 -0.009 0.135 -9.892 0.439 0.456 0.463
eps -0.026 -0.007 0.098 -6.84 0.3 0.32 0.33
epsdiluted -0.026 -0.007 0.082 -6.84 0.25 0.27 0.28
weightedAverageShsOut 158M 156M 156M 155M 154M 153M 153M
weightedAverageShsOutDil 158M 156M 187M 155M 187M 185M 184M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IRWD IRWD IRWD IRWD IRWD IRWD IRWD
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-09 2024-02-16 2023-11-09 2023-08-09 2023-05-04 2023-02-16 2022-11-03
acceptedDate 2024-05-09 16:46:11 2024-02-16 07:01:34 2023-11-09 16:18:17 2023-08-09 16:02:57 2023-05-04 16:05:54 2023-02-16 17:21:07 2022-11-03 16:06:19
calendarYear 2024 2023 2023 2023 2023 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 122M 92M 110M 175M 740M 656M 574M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 122M 92M 110M 175M 740M 656M 574M
netReceivables 72M 129M 125M 119M 116M 115M 117M
inventory 0 1 788 000 788 000 1M 1M 0
otherCurrentAssets 15M 12M 18M 23M 9M 8M 8M
totalCurrentAssets 208M 233M 254M 318M 866M 781M 699M
propertyPlantEquipmentNet 17M 18M 19M 19M 20M 20M 21M
goodwill 0 0 0 0 0 0 0
intangibleAssets 3M 4M 4M 4M 0 0 0
goodwillAndIntangibleAssets 3M 4M 4M 4M 0 0 0
longTermInvestments 0 -1 510 000 0 0 0 0
taxAssets 206M 212M 244M 258M 268M 284M 305M
otherNonCurrentAssets 3M 4M 4M 4M 1M 16M 16M
totalNonCurrentAssets 231M 238M 270M 286M 289M 320M 341M
otherAssets 0 1 0 0 0 0 0
totalAssets 439M 471M 524M 603M 1 155M 1 101M 1 040M
accountPayables 6M 8M 5M 4M 118 000 483 000 795 000
shortTermDebt 203M 203M 202M 202M 3M 3M 3M
taxPayables 2M 1M 1M 7M 0 0 0
deferredRevenue 2M 1M 59M 0 0 0 0
otherCurrentLiabilities 41M 64M 14M 100M 21M 22M 23M
totalCurrentLiabilities 252M 276M 281M 305M 24M 26M 27M
longTermDebt 473M 498M 538M 614M 413M 413M 413M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 43M 43M 31M 31M 12M 10M 418M
totalNonCurrentLiabilities 517M 541M 569M 645M 425M 423M 422M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 14M 15M 18M 19M 19M 20M 20M
totalLiabilities 769M 817M 850M 950M 448M 448M 449M
preferredStock 0 0 0 0 0 0 0
commonStock 159 000 156 000 156 000 156 000 155 000 154 000 153 000
retainedEarnings -1 703M -1 699M -1 698M -1 713M -651M -696M -745M
accumulatedOtherComprehensiveIncomeLoss -922 000 -3M -752 000 0 0 0 0
othertotalStockholdersEquity 1 373M 1 355M 1 372M 1 366M 1 357M 1 349M 1 336M
totalStockholdersEquity -331M -346M -326M -347M 707M 652M 591M
totalEquity -331M -346M -328M -348M 707M 652M 591M
totalLiabilitiesAndStockholdersEquity 439M 471M 524M 603M 1 155M 1 101M 1 040M
minorityInterest 0 0 -2M -1M 0 0 0
totalLiabilitiesAndTotalEquity 439M 471M 524M 603M 1 155M 1 101M 1 040M
totalInvestments 0 -1 510 000 0 0 0 0
totalDebt 690M 716M 741M 816M 416M 416M 416M
netDebt 569M 623M 630M 640M -325M -240M -158M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IRWD IRWD IRWD IRWD IRWD IRWD IRWD
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-09 2024-02-16 2023-11-09 2023-08-09 2023-05-04 2023-02-16 2022-11-03
acceptedDate 2024-05-09 16:46:11 2024-02-16 07:01:34 2023-11-09 16:18:17 2023-08-09 16:02:57 2023-05-04 16:05:54 2023-02-16 17:21:07 2022-11-03 16:06:19
calendarYear 2024 2023 2023 2023 2023 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -4M -1M 14M -1 089M 46M 49M 50M
depreciationAndAmortization 513 000 512 000 507 000 270 000 286 000 340 000 363 000
deferredIncomeTax 6M 31M 14M 10M 17M 20M 16M
stockBasedCompensation 8M 9M 8M 8M 7M 7M 7M
changeInWorkingCapital 34M -9M -5M 15M 10M 2M -5M
accountsReceivables 57M -5M -6M -3M 14M 937 000 -14M
inventory 0 0 0 0 0 0 0
accountsPayables -13M -13M 7M 18M 705 000 -2M 5M
otherWorkingCapital -11M 9M -6M 578 000 -15M 3M 5M
otherNonCashItems -35M 5M 586 000 1 091M 383 000 420 000 249 000
netCashProvidedByOperatingActivities 45M 36M 32M 35M 80M 79M 69M
investmentsInPropertyPlantAndEquipment -68 000 -211 000 -49 000 0 -13 000 27 000 -66 000
acquisitionsNet 0 -4M -23M 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites 0 1 -23M -999M 0 0 0
netCashUsedForInvestingActivites -68 000 -4M -23M -999M -13 000 27 000 -66 000
debtRepayment -25M -23M -75M 0 0 0 0
commonStockIssued 10M 998 000 12 000 0 4M 10M 0
commonStockRepurchased 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -616 000 -29M -75M 399M 0 -7M 797 000
netCashUsedProvidedByFinancingActivities -16M -51M -75M 399M 4M 3M 797 000
effectOfForexChangesOnCash 24 000 -50 000 -3000 -35M 0 0 0
netChangeInCash 29M -19M -65M -565M 84M 82M 70M
cashAtEndOfPeriod 122M 92M 111M 177M 742M 658M 576M
cashAtBeginningOfPeriod 92M 111M 177M 742M 658M 576M 506M
operatingCashFlow 45M 36M 32M 35M 80M 79M 69M
capitalExpenditure -68 000 -211 000 -49 000 0 -13 000 27 000 -66 000
freeCashFlow 45M 36M 32M 35M 80M 79M 69M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-09 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
2024-05-06 20:01 ET
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
2024-05-02 18:33 ET
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
2024-05-01 11:30 ET
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
2024-04-25 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
2024-03-28 11:30 ET
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
2024-02-29 11:00 ET
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
2024-02-23 12:30 ET
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
2024-02-15 12:00 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
2024-02-01 21:01 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
2024-01-09 00:00 ET
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
2024-01-08 11:00 ET
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
2024-01-03 21:01 ET
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 21:01 ET
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
2023-11-30 14:45 ET
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
2023-11-21 21:01 ET
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
2023-11-09 12:00 ET
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
2023-10-26 20:01 ET
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
2023-10-23 11:30 ET
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
2023-10-16 10:00 ET
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
2023-10-05 11:30 ET
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
2023-08-08 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
2023-07-25 20:01 ET
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
2023-06-29 12:30 ET
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
2023-06-16 11:00 ET
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
2023-06-12 20:05 ET
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
2023-05-22 10:57 ET
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
2023-05-09 20:01 ET
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
2023-05-08 11:30 ET
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
2023-05-04 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
2023-04-24 11:30 ET
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
2023-04-20 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
2023-02-27 21:01 ET
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-02-16 12:00 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
2023-02-13 12:30 ET
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
2023-02-02 21:01 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
2023-01-09 11:00 ET
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
2023-01-04 21:01 ET
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-22 21:01 ET
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
2022-11-03 11:01 ET
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
2022-10-20 20:01 ET
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
2022-09-06 11:00 ET
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
2022-09-01 20:01 ET
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
2022-08-04 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
2022-07-21 20:01 ET
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
2022-05-25 11:30 ET
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
2022-05-09 12:00 ET
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
2022-05-05 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
2022-04-21 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
2022-03-02 12:30 ET
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
2022-02-17 12:00 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
2022-02-03 12:30 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
2022-01-10 12:20 ET
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
2022-01-05 12:30 ET
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-01 12:30 ET
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
2021-11-04 11:15 ET
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
2021-11-04 11:00 ET
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
2021-10-25 11:30 ET
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
2021-10-21 11:00 ET
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
2021-09-02 11:30 ET
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
2021-08-26 11:00 ET
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
2021-08-05 11:00 ET
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
2021-08-03 11:30 ET
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
2021-07-22 20:01 ET
Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
2021-06-16 11:45 ET
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
2021-06-07 20:01 ET
Ironwood Pharmaceuticals Announces Leadership Updates
2021-05-26 20:01 ET
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
2021-05-24 12:00 ET
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
2021-05-17 12:30 ET
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
2021-05-06 11:03 ET
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
2021-05-06 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
2021-04-22 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call
2021-02-19 21:01 ET
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
2021-02-17 12:01 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
2021-02-08 21:01 ET
Ironwood Pharmaceuticals Announces CEO Transition
2021-02-03 21:01 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
2021-01-05 12:30 ET
Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-03 13:30 ET
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
2020-11-06 21:01 ET
Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference
2020-11-05 21:03 ET
Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance
2020-11-05 21:01 ET
Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors
2020-10-22 20:01 ET
Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call
2020-09-29 11:15 ET
Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
2020-09-02 20:00 ET
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
2020-08-06 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
2020-07-23 20:05 ET
Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
2020-07-21 11:00 ET
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
2020-05-27 12:00 ET
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
2020-05-06 20:05 ET
Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
2020-04-28 20:05 ET
Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
2020-04-16 20:05 ET
Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call
2020-03-26 13:00 ET
Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
2020-02-26 21:05 ET
Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
2020-02-25 21:05 ET
Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences
2020-02-19 21:05 ET
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
2020-02-13 12:00 ET
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
2020-01-30 21:05 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call
2020-01-22 14:20 ET
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation
2020-01-06 13:00 ET
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
2020-01-02 21:01 ET
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
2019-11-05 21:05 ET
Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
2019-10-31 11:00 ET
Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance
2019-10-28 12:00 ET
Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting
2019-10-17 20:05 ET
Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call
2019-09-18 06:00 ET
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
2019-04-16 20:02 ET
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
2019-04-01 20:02 ET
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
2019-03-14 20:54 ET
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement